Newsletter Tool

Today’s Big News

Jul 10, 2025

FDA releases ‘initial batch’ of more than 200 drug rejection letters

AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer in blood cancer

Eolas regains opioid use disorder drug abandoned by AstraZeneca

Lack of early win for Ultragenyx, Mereo’s bone disorder med dents stock, but analysts keep faith

Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo

Fierce Biotech Layoff Tracker 2025: Century Tx halves staff and cuts 2 C-suite roles

New compounds kill the parasite that causes Chagas disease in mice by disrupting protein synthesis

Fierce Biotech Fundraising Tracker '25: Renasant reels in $54.5M in seed funding; Nuclidium nabs $99M

Featured

FDA releases ‘initial batch’ of more than 200 drug rejection letters

By Gabrielle Masson

The FDA has released an "initial batch" of more than 200 complete response letters (CRLs) in efforts to boost transparency.

AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer in blood cancer

By Nick Paul Taylor

AbbVie is paying Ichnos Glenmark Innovation $700 million upfront for a next-generation rival to Johnson & Johnson’s Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma patients.

Eolas regains opioid use disorder drug abandoned by AstraZeneca

By James Waldron

AZ ended work on the orexin 1 receptor antagonist in November after a phase 2 study identified a “potential drug-drug interaction" with the widely used antifungal itraconazole.

SAP, Answerthink Help Emerging Biopharma Firms Scale With Confidence

Lack of early win for Ultragenyx, Mereo’s bone disorder med dents stock, but analysts keep faith

By James Waldron

Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicine despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trial.

Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo

By James Waldron

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical journey of its copper-based radiopharmaceutical diagnostic and therapeutic offering.

Fierce Biotech Layoff Tracker 2025: Century Tx halves staff and cuts 2 C-suite roles

By Gabrielle Masson,Darren Incorvaia

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

New compounds kill the parasite that causes Chagas disease in mice by disrupting protein synthesis

By Darren Incorvaia

Scientists have identified a new class of compounds capable of partially clearing the tropical parasite that causes Chagas disease out of mice, suggesting the molecular group could serve as a source of new treatments for one of the deadliest parasitic infections in the world.

Fierce Biotech Fundraising Tracker '25: Renasant reels in $54.5M in seed funding; Nuclidium nabs $99M

By Gabrielle Masson,Darren Incorvaia,James Waldron

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

Medtronic treats first patient in multi-organ denervation study for high blood pressure

By Conor Hale

The company said its pilot program completed its first patient procedure that delivered the hypertension therapy to the renal arteries as well as the vessels feeding the liver.

RFK Jr. cancels USPSTF meeting as healthcare orgs urge Congress to 'protect integrity' of expert panel

By Heather Landi

The office of HHS Secretary Robert F. Kennedy Jr. abruptly called off a meeting of the U.S. Preventive Services Task Force scheduled for Thursday, as many healthcare experts are concerned about potential political interference that could sideline independent experts.

Fierce podcasts

Don’t miss an episode

What employers want from specialty care

In this episode of "Podnosis," we explore why some employers are turning to value-based specialty care as a strategy to control costs and improve care quality.

Rethinking the mental healthcare model

Teva’s CEO shares ‘Pivot to Growth’ progress

Resources

Whitepaper

Industry-backed, data-driven approaches to enhancing container closure integrity

This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance.

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.